April 22, 2020 03:05 PM EDTUpdated April 23, 04:41 AM
Financing
R&D
Pharma
Cell/Gene Tx

Analy­sis shows Swiss biotech in­dex out­shines Nas­daq coun­ter­part, but coro­n­avirus chal­lenges are uni­ver­sal

Natalie Grover

Reporter

In 2004, the Swiss Stock Ex­change spawned its biotech in­dex — the Swiss Bio+Medtech In­dex (SXI) — as the life sci­ences sec­tor, head­lined by large suc­cess­ful bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times